1 month EDIT Inks Collaboration Deal to Develop Novel Gene Editing TherapiesZacks
Editas signs a license agreement with Genevant Sciences to develop novel mRNA-LNP gene editing therapeutics. Shares rise in after-hours trading.
XEditas signs a license agreement with Genevant Sciences to develop novel mRNA-LNP gene editing therapeutics. Shares rise in after-hours trading.
X